AndroGel MDL Motion Filed to Centralize Testosterone Gel Lawsuits

A request has been filed with the U.S. Judicial Panel on Multidistrict Litigation (JPML) to consolidate all AndroGel lawsuits filed throughout the federal court system, centralizing the cases before one judge for coordinated handling during pretrial proceedings.

According to Motion to Transfer (PDF) filed on March 28, there are currently at least 38 product liability lawsuits filed in U.S. District Courts throughout the country involving similar allegations that side effects of Androgel testosterone caused plaintiffs to suffer heart attacks, strokes, blood clots and other cardiovascular problems, including death.

A group of plaintiffs are requesting that all cases be centralized in the U.S. District Court for the Northern District of Illinois as part of an Androgel MDL, or Multidistrict Litigation.

Did You Know?

AT&T Data Breach Impacts Millions of Customers

More than 73 million customers of AT&T may have had their names, addresses, phone numbers, Social Security numbers and other information released on the dark web due to a massive AT&T data breach. Lawsuits are being pursued to obtain financial compensation.

Learn More

AndroGel is the leading testosterone replacement therapy, which is delivered through a gel pump. All of the lawsuits involve similar allegations that the drug maker AbbVie failed to adequately warn men about the risk of heart problems from AndroGel.

The MDL motion requests that all cases be centralized before U.S. District Court Judge Matthew F. Kennelly, who is already presiding over the Androgel litigation in the Northern District of Illinois. At least 36 of the cases pending nationwide have been filed in Illinois, with additional cases pending in Colorado and Pennsylvania.

As testosterone injury lawyers continue to review and file cases throughout the United States, it is ultimately expected that hundreds, if not thousands, of lawsuits will be brought against AbbVie in courts throughout the country.

Centralizing the federal Androgel testosterone cases before one judge is designed to reduce the risk of duplicative discovery in hundreds of cases, avoid conflicting rulings from different judges and to serve the convenience of the parties, witnesses and the courts.

Testosterone Treatment Litigation

In recent months, AbbVie and other pharmaceutical companies have faced a growing number of claims over the popular low testosterone treatments, claiming that the drug makers withheld important information from consumers and the medical community. In addition lawsuits over Androgel, a number of Testim lawsuits, AndroDerm lawsuits, Axiron lawsuits and other testosterone treatment lawsuits are being investigated nationwide.

The cases come after a series of studies have raised concerns about the link between testosterone and heart attacks.

In January 2014, a study was published in the medical journal PLOSOne, which found that low testosterone treatments may double the risk of heart attack for younger men with heart disease and men over the age of 65, regardless of their prior heart conditions.

This research was a follow up to a November 2013 study published in the Journal of the American Medical Association that suggested side effects of testosterone may increase the risk of heart attacks, strokes, and death among older men with certain pre-existing heart problems.

In response to the findings, the FDA launched a safety review of AndroGel and other testosterone replacement therapy on January 31, leading to multiple media reports about the potential risk and lawyers advertising for potential claims.

The complaints involve allegations that the manufacturers essentially created the “disease” of low testosterone among men, blaming everything from fatigue to grumpiness on “Low T.” However, originally, the testosterone drugs were approved by the FDA to treat medically discernable low testosterone levels caused by a medical condition, such as hypogonadism. The condition was at first estimated to affect only about a million men in the U.S., but now the pharmaceutical industry estimates a 20 million man market for testosterone drugs.

1 Comments

  • MichaelJuly 11, 2014 at 8:28 pm

    I experienced pain, swelling in both legs and ankles, which became unbearable. Doctors could not identify what was causing my swelling which included the rest of my body. I had decreased penile erections with what appeared to be Peyronie's Disease. Loss of ability function sexually. I was already a heart patient and very close to experiencing a hear attack before quitting Androgel with seve[Show More]I experienced pain, swelling in both legs and ankles, which became unbearable. Doctors could not identify what was causing my swelling which included the rest of my body. I had decreased penile erections with what appeared to be Peyronie's Disease. Loss of ability function sexually. I was already a heart patient and very close to experiencing a hear attack before quitting Androgel with severe anxiety attacks and night sweats. All of these issues are improving I am left with many hours of pain and suffering even after the fact.

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Court Allows Suboxone Tooth Decay Lawsuits To Be Filed in Bundled Complaint by June 14, 2024
Court Allows Suboxone Tooth Decay Lawsuits To Be Filed in Bundled Complaint by June 14, 2024 (Posted 2 days ago)

A federal judge is allowing plaintiffs to file large numbers of Suboxone tooth decay lawsuits in one bundled complaint, to meet a potential two-year statute of limitations deadline, with the ability to flesh those claims out in more detail at a later date.